Hemophilia A Clinical Trial
Official title:
Evaluation of Real World Outcomes With Extended Half-Life Concentrates for Routine Clinical Use in Haemophilia A and B: UK - EHL Outcomes Registry
| NCT number | NCT02938156 |
| Other study ID # | RFH/9782 |
| Secondary ID | |
| Status | Recruiting |
| Phase | |
| First received | |
| Last updated | |
| Start date | December 17, 2016 |
| Est. completion date | October 2019 |
| Verified date | August 2018 |
| Source | Royal Free Hospital NHS Foundation Trust |
| Contact | Emal Waqif |
| emal.waqif[@]nhs.net | |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Severe haemophilia A and B (SHA, SHB) are inherited bleeding disorders affecting male
patients and are characterised by low levels of circulating clotting factors VIII and IX
respectively. Clinically low levels present with multiple recurrent bleeds into joints and
muscle from the first couple of years of life. In addition patients may present with
spontaneous and potentially fatal bleeding into any organ. The mainstay of treatment is
replacement with the missing factor in the form of intravenous injections of factor VIII and
IX. Clotting factors can be given to treat a bleed or can be given to prevent a bleed, and
the latter is termed prophylaxis. Regular prophylaxis is the current standard of care and
aims to decrease spontaneous bleeding events and resulting joint damage, and this requires
patients to self-infuse factor into their veins two to four times week. Patient's compliance
with prescribed regimen and recommendations has a significant influence on outcomes.
Advances in biomolecular and protein engineering have extended the duration of the effect of
clotting factor VIII and IX through multiple mechanisms. This extension of the duration of
the effect presents the clinician and patients with opportunities to tailor the treatment to
their particular needs, circumstances and body other characteristics. It has been suggested
that decreasing the frequency of infusions will improve adherence and thus contribute to
improved outcomes.
In rare disorders, it is an accepted fact that post-marketing studies are crucial to
understand the generalisability of the efficacy and safety outcomes and identify any new
safety and efficacy concerns in relation to specific population group. The investigators
propose the development of a registry for systematic collection of information with the dual
aim of analysing the relationship between patient and treatment characteristics, and
outcomes, and simultaneously identify areas for practice development that can improve the
overall quality of life experienced by the haemophilia patient community.
| Status | Recruiting |
| Enrollment | 500 |
| Est. completion date | October 2019 |
| Est. primary completion date | October 2019 |
| Accepts healthy volunteers | No |
| Gender | Male |
| Age group | N/A and older |
| Eligibility |
Inclusion Criteria: 1. Patients with Haemophilia A or B requiring replacement therapy 2. Patients or parents able to provide informed consent 3. Patients being considered for use of EHL - CFC. Exclusion Criteria: 1. Patients currently enrolled into a clinical trial of investigational medicinal product. |
| Country | Name | City | State |
|---|---|---|---|
| United Kingdom | Basingstoke and North Hampshire Hospital | Basingstoke | |
| United Kingdom | Birmingham Women and Childrens | Birmingham | |
| United Kingdom | Queen Elizabeth Hospital | Birmingham | |
| United Kingdom | University Hospital Bristol | Bristol | |
| United Kingdom | Kent & Canterbury Hospital | Canterbury | |
| United Kingdom | University Hospital of Wales | Cardiff | |
| United Kingdom | University of Coventry & Warwickshire | Coventry | |
| United Kingdom | Glasgow Royal Hospital for Children | Glasgow | |
| United Kingdom | Royal Infirmary | Glasgow | |
| United Kingdom | Lincoln County Hospital | Lincoln | |
| United Kingdom | Liverpool University Hospital | Liverpool | |
| United Kingdom | Great Ormond Street Hospital | London | |
| United Kingdom | Hammersmith Hospital | London | |
| United Kingdom | Royal Free Hospital NHS Foundation Trust | London | |
| United Kingdom | St George's Hospital | London | |
| United Kingdom | Royal Victoria Hospital | Newcastle upon Tyne | |
| United Kingdom | Nottingham University Hospital | Nottingham | |
| United Kingdom | Churchill Hospital Oxford | Oxford | |
| United Kingdom | Royal Hallamshire Hospital | Sheffield | |
| United Kingdom | Sheffield Children's Hospital | Sheffield | |
| United Kingdom | Royal Cornwall Hospital | Truro |
| Lead Sponsor | Collaborator |
|---|---|
| Royal Free Hospital NHS Foundation Trust |
United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Bleed Control | Investigate changes to bleed control using questionnaire & Haemtrack (software package to record therapy received | 2 years post enrolment | |
| Primary | Joint Health | Target joint assessment and questionnaire | 2 years post enrolment | |
| Secondary | EQ-5D-5L | Patient Questionnaire | 2 years post enrolment | |
| Secondary | HAEM-A-QoL | Patient Questionnaire | 2 years post enrolment | |
| Secondary | Haemo-QoL | Patient Questionnaire | 2 years post enrolment | |
| Secondary | Physical Activity QoL | Patient Questionnaire | 2 years post enrolment | |
| Secondary | Haemoprefer | Patient Questionnaire | 2 years post enrolment | |
| Secondary | Identify the value of individualised prophylaxis | Patient questionnaire | 5 years |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03834727 -
Characterizing the Impact and Treatment of Reproductive Tract Bleeding on Women and Post-menarchal Girls With Bleeding Disorders
|
||
| Completed |
NCT03191799 -
A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors
|
Phase 3 | |
| Completed |
NCT01599819 -
BAX 855 Dose-Escalation Safety Study
|
Phase 1 | |
| Terminated |
NCT04541628 -
Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A
|
Phase 1/Phase 2 | |
| Completed |
NCT02847637 -
A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors
|
Phase 3 | |
| Completed |
NCT04072237 -
Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia
|
Phase 1 | |
| Completed |
NCT04085458 -
Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation)
|
Phase 4 | |
| Completed |
NCT04565236 -
A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A
|
Phase 4 | |
| Recruiting |
NCT05987449 -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04621916 -
Preventing Inhibitor Recurrence Indefinitely
|
Phase 4 | |
| Not yet recruiting |
NCT02888223 -
Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A
|
Phase 1 | |
| Completed |
NCT02528968 -
National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A
|
N/A | |
| Completed |
NCT02225483 -
Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function
|
N/A | |
| Completed |
NCT02199717 -
An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia
|
N/A | |
| Completed |
NCT01217255 -
Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World
|
||
| Completed |
NCT00969319 -
Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America
|
N/A | |
| Terminated |
NCT00995046 -
Individually Tailored Prophylaxis in Patients With Severe Hemophilia A
|
N/A | |
| Completed |
NCT00868530 -
Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects
|
Phase 3 | |
| Completed |
NCT00839202 -
Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay
|
N/A | |
| Completed |
NCT00629837 -
Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980
|
Phase 1 |